{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-024814","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.744851+00:00","generated_at":"2026-05-26T23:04:03.538834+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Alto Neuroscience reports favorable ALTO-300 Phase 2b interim analysis; final data expected mid-2026","bullets":["Planned interim analysis recommended continuing study with ~200 biomarker-positive patients in final sample.","Topline results from the Phase 2b trial of ALTO-300 are expected in mid-2026.","Company reported preliminary 2024 year-end cash of ~$168M, expected to fund operations into 2028.","Interim analysis included 87 biomarker-positive patients after in-depth site and patient eligibility review."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-024814","json":"https://secwatch.observer/filing/0001193125-25-024814.json","markdown":"https://secwatch.observer/filing/0001193125-25-024814.md","text":"https://secwatch.observer/filing/0001193125-25-024814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000119312525024814/0001193125-25-024814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000119312525024814/d876505d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:04:03.538834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}